NeutralLOW severityHealthcare & Pharma2d ago

Health Catalyst CEO Simeon Kohl acquires $105,438 in company stock

Health Catalyst CEO Simeon Kohl acquires $105,438 in company stock — $HCAT one-month chart
$HCAT daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Health Catalyst is near the bottom of its 52-week range, trading at $1.51 after a 11.03% jump, with most recent coverage arriving in the last week and described as neutral. The Health Care sector shows calm, but the story was published over the weekend, so fresh momentum may take time to materialize.

Written by Wook AI Nov 15, 7:38 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about HCAT. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · health catalystEvent risk Low

Nothing reported about health catalyst across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 100% a year
Now $1.37Week $1.18–$1.56 (±14.1%)Month $0.975–$1.77 (±28.9%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: $HCAT's deal is more than a number — the real story lies in the details, like financing and regulatory hurdles, which often decide the outcome.
  • How the stock is trading: $HCAT -0.72% in the latest session.
  • Timing: It came out on a weekend, so the change shown is Friday's and Monday's open is the first chance to trade on it. Market holidays are not detected.
Amount$105,438

Where the stock stands

Health Catalyst ($HCAT) slipped 0.72% to $1.37 in the latest session. Over the past month it is down 19.9%. It now sits 55% under the 52-week high of $3.03 and 43% above the year's low of $0.96. It has been a volatile year: the high was 3.2 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Nov 5, 2026), $HCAT earned $40.5M over the quarter to Sep 30, 2026 on revenue of $56.3M (-20.2% QoQ). Operations brought in $16.9M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $16.1M. Its most recent filings before this story: 10-Q on Nov 5, 2026, 8-K on Nov 5, 2026, 8-K on Sep 14, 2026. Figures are as filed with the SEC; the $HCAT page has the full statements.

How much coverage it is getting

This is the only story on Health Catalyst in Wook's last 30 days of coverage, so there is no recent run to compare it with.

The bigger picture

Healthcare news is shaped by trials, approvals, and pricing — one decision can shift a drugmaker's fate, while policy changes ripple across the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

Check $HCAT's filings for the straight scoop. Compare how different outlets spin the same event to see what's fact and what's flair. Wook AI can help track how far $HCAT has moved from its peak.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 15, 2026. $HCAT has moved -19.88% ($1.71 to $1.37). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy